Equillium, Inc. — Director's Dealing 2021

Oct 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Equillium, Inc. (EQ)
CIK: 0001746466
Period of Report: 2021-10-06

Reporting Person: Connelly Stephen (Director, Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-06	Common Stock	M	5625	$4.75	Acquired	998625	Direct
2021-10-06	Common Stock	S	5625	$7.0077	Disposed	993000	Direct
2021-10-06	Common Stock	M	2467	$2.80	Acquired	995467	Direct
2021-10-06	Common Stock	S	2467	$7.0076	Disposed	993000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-06	Employee Stock Option (right to buy)	$4.75	M	5625	Disposed	2029-12-09	Common Stock (5625)	Direct
2021-10-06	Employee Stock Option (right to buy)	$2.80	M	2467	Disposed	2030-05-18	Common Stock (2467)	Direct

Footnotes

F1: The transactions reported on this form were effected pursuant to a 10b5-1 trading plan adopted by the filer on March 31, 2021.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.05 to $7.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.06 to $7.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.

F4: This option, representing a right to purchase twenty-five percent of the shares subject to the grant, became exercisable on December 10, 2020, which was the first anniversary of the date on which the option was granted, the remaining portion of this option vests in 36 equal monthly installments thereafter.

F5: This option, representing a right to purchase twenty-five percent of the shares subject to the grant, became exercisable on May 19, 2021, which was the first anniversary of the date on which the option was granted, the remaining portion of this option vests in 36 equal monthly installments thereafter.